+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Future of Alcohol Addiction R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • ID: 4749271
  • Report
  • February 2019
  • Region: Global
  • 120 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Astraea Therapeutics LLC
  • Chronos Therapeutics Ltd
  • Ethypharm SA
  • Johnson & Johnson
  • Montisera Ltd
  • MORE
The global demand for Alcohol Addiction treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Alcohol Addiction pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Alcohol Addiction pipeline companies from advancing their products into Phase 3 or Phase 4.

Alcohol Addiction Report Description

The 2019 pipeline study on Alcohol Addiction pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Alcohol Addiction pipeline compounds.

The Alcohol Addiction pipeline guide presents information on all active drugs currently being developed for Alcohol Addiction. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Alcohol Addiction pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Alcohol Addiction drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Alcohol Addiction product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Alcohol Addiction pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Alcohol Addiction pipeline report includes
  • An overview of Alcohol Addiction disease including symptoms, causes, diagnosis and available treatment options is provided.
  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
  • Phase wise count of Alcohol Addiction pipeline
  • Company wise list of Alcohol Addiction pipeline
  • Mechanism of Action wise Alcohol Addiction pipeline
For each pipeline candidate, the following details are provided:
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
  • Current status of development
  • Drug overview
  • Mechanism of Action
  • Pre-clinical and Clinical Trials/Results
  • Company Overview and Recent Developments
Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations
  • Get clear understanding of the entire Alcohol Addiction pipeline, with details on active projects
  • Stay ahead of the competition through comprehensive knowledge of Alcohol Addiction pipeline progress
  • Get in detail information of each product with updated information on each project along with key milestones
  • Gain clear insights into companies participating in Alcohol Addiction pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
The report will be delivered in 2 working days.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Astraea Therapeutics LLC
  • Chronos Therapeutics Ltd
  • Ethypharm SA
  • Johnson & Johnson
  • Montisera Ltd
  • MORE
1.1 List of Tables
1.2 List of Figures

2. Global Alcohol Addiction Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. Executive Summary
3.1 Alcohol Addiction Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Alcohol Addiction pipeline, H1- 2019
3.5 Mechanism of Action wise Alcohol Addiction Pipeline Candidates

4 AbbVie Inc Alcohol Addiction Pipeline Details
4.1 AbbVie Inc Business Profile
4.2 AbbVie Inc Alcohol Addiction Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 Addex Therapeutics Ltd Alcohol Addiction Pipeline Details
5.1 Addex Therapeutics Ltd Business Profile
5.2 Addex Therapeutics Ltd Alcohol Addiction Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 Adial Pharmaceuticals LLC Alcohol Addiction Pipeline Details
6.1 Adial Pharmaceuticals LLC Business Profile
6.2 Adial Pharmaceuticals LLC Alcohol Addiction Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 Amygdala Neurosciences Inc Alcohol Addiction Pipeline Details
7.1 Amygdala Neurosciences Inc Business Profile
7.2 Amygdala Neurosciences Inc Alcohol Addiction Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 Arbor Pharmaceuticals LLC Alcohol Addiction Pipeline Details
8.1 Arbor Pharmaceuticals LLC Business Profile
8.2 Arbor Pharmaceuticals LLC Alcohol Addiction Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 Assuage Pharmaceuticals Inc Alcohol Addiction Pipeline Details
9.1 Assuage Pharmaceuticals Inc Business Profile
9.2 Assuage Pharmaceuticals Inc Alcohol Addiction Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 Astraea Therapeutics LLC Alcohol Addiction Pipeline Details
10.1 Astraea Therapeutics LLC Business Profile
10.2 Astraea Therapeutics LLC Alcohol Addiction Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11 AstraZeneca Plc Alcohol Addiction Pipeline Details
11.1 AstraZeneca Plc Business Profile
11.2 AstraZeneca Plc Alcohol Addiction Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12 BioCorRx Inc Alcohol Addiction Pipeline Details
12.1 BioCorRx Inc Business Profile
12.2 BioCorRx Inc Alcohol Addiction Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13 Bionex Pharmaceuticals LLC Alcohol Addiction Pipeline Details
13.1 Bionex Pharmaceuticals LLC Business Profile
13.2 Bionex Pharmaceuticals LLC Alcohol Addiction Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14 Bioprojet SCR Alcohol Addiction Pipeline Details
14.1 Bioprojet SCR Business Profile
14.2 Bioprojet SCR Alcohol Addiction Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15 Chronos Therapeutics Ltd Alcohol Addiction Pipeline Details
15.1 Chronos Therapeutics Ltd Business Profile
15.2 Chronos Therapeutics Ltd Alcohol Addiction Drug Details
15.3 Drug Snapshot
15.3.1 Originator
15.3.2 Collaborator/Co-Developer
15.3.3 Route of Administration
15.3.4 Orphan Drug/Fast Track/Special Designation
15.3.5 Geography
15.3.6 Type of Molecular Entity
15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments

16 Corcept Therapeutics Inc Alcohol Addiction Pipeline Details
16.1 Corcept Therapeutics Inc Business Profile
16.2 Corcept Therapeutics Inc Alcohol Addiction Drug Details
16.3 Drug Snapshot
16.3.1 Originator
16.3.2 Collaborator/Co-Developer
16.3.3 Route of Administration
16.3.4 Orphan Drug/Fast Track/Special Designation
16.3.5 Geography
16.3.6 Type of Molecular Entity
16.3.7 Current Status
16.4 Drug Overview
16.5 Drug Mechanism of Action
16.6 Clinical/Pre-clinical Trial Details
16.7 Latest Drug Developments

17 Curemark LLC Alcohol Addiction Pipeline Details
17.1 Curemark LLC Business Profile
17.2 Curemark LLC Alcohol Addiction Drug Details
17.3 Drug Snapshot
17.3.1 Originator
17.3.2 Collaborator/Co-Developer
17.3.3 Route of Administration
17.3.4 Orphan Drug/Fast Track/Special Designation
17.3.5 Geography
17.3.6 Type of Molecular Entity
17.3.7 Current Status
17.4 Drug Overview
17.5 Drug Mechanism of Action
17.6 Clinical/Pre-clinical Trial Details
17.7 Latest Drug Developments

18 EpiVario Inc Alcohol Addiction Pipeline Details
18.1 EpiVario Inc Business Profile
18.2 EpiVario Inc Alcohol Addiction Drug Details
18.3 Drug Snapshot
18.3.1 Originator
18.3.2 Collaborator/Co-Developer
18.3.3 Route of Administration
18.3.4 Orphan Drug/Fast Track/Special Designation
18.3.5 Geography
18.3.6 Type of Molecular Entity
18.3.7 Current Status
18.4 Drug Overview
18.5 Drug Mechanism of Action
18.6 Clinical/Pre-clinical Trial Details
18.7 Latest Drug Developments

19 Ethypharm SA Alcohol Addiction Pipeline Details
19.1 Ethypharm SA Business Profile
19.2 Ethypharm SA Alcohol Addiction Drug Details
19.3 Drug Snapshot
19.3.1 Originator
19.3.2 Collaborator/Co-Developer
19.3.3 Route of Administration
19.3.4 Orphan Drug/Fast Track/Special Designation
19.3.5 Geography
19.3.6 Type of Molecular Entity
19.3.7 Current Status
19.4 Drug Overview
19.5 Drug Mechanism of Action
19.6 Clinical/Pre-clinical Trial Details
19.7 Latest Drug Developments

20 H. Lundbeck AS Alcohol Addiction Pipeline Details
20.1 H. Lundbeck AS Business Profile
20.2 H. Lundbeck AS Alcohol Addiction Drug Details
20.3 Drug Snapshot
20.3.1 Originator
20.3.2 Collaborator/Co-Developer
20.3.3 Route of Administration
20.3.4 Orphan Drug/Fast Track/Special Designation
20.3.5 Geography
20.3.6 Type of Molecular Entity
20.3.7 Current Status
20.4 Drug Overview
20.5 Drug Mechanism of Action
20.6 Clinical/Pre-clinical Trial Details
20.7 Latest Drug Developments

21 Heptares Therapeutics Ltd Alcohol Addiction Pipeline Details
21.1 Heptares Therapeutics Ltd Business Profile
21.2 Heptares Therapeutics Ltd Alcohol Addiction Drug Details
21.3 Drug Snapshot
21.3.1 Originator
21.3.2 Collaborator/Co-Developer
21.3.3 Route of Administration
21.3.4 Orphan Drug/Fast Track/Special Designation
21.3.5 Geography
21.3.6 Type of Molecular Entity
21.3.7 Current Status
21.4 Drug Overview
21.5 Drug Mechanism of Action
21.6 Clinical/Pre-clinical Trial Details
21.7 Latest Drug Developments

22 Indivior Plc Alcohol Addiction Pipeline Details
22.1 Indivior Plc Business Profile
22.2 Indivior Plc Alcohol Addiction Drug Details
22.3 Drug Snapshot
22.3.1 Originator
22.3.2 Collaborator/Co-Developer
22.3.3 Route of Administration
22.3.4 Orphan Drug/Fast Track/Special Designation
22.3.5 Geography
22.3.6 Type of Molecular Entity
22.3.7 Current Status
22.4 Drug Overview
22.5 Drug Mechanism of Action
22.6 Clinical/Pre-clinical Trial Details
22.7 Latest Drug Developments

23 Johnson & Johnson Alcohol Addiction Pipeline Details
23.1 Johnson & Johnson Business Profile
23.2 Johnson & Johnson Alcohol Addiction Drug Details
23.3 Drug Snapshot
23.3.1 Originator
23.3.2 Collaborator/Co-Developer
23.3.3 Route of Administration
23.3.4 Orphan Drug/Fast Track/Special Designation
23.3.5 Geography
23.3.6 Type of Molecular Entity
23.3.7 Current Status
23.4 Drug Overview
23.5 Drug Mechanism of Action
23.6 Clinical/Pre-clinical Trial Details
23.7 Latest Drug Developments

24 Kinnov Therapeutics SAS Alcohol Addiction Pipeline Details
24.1 Kinnov Therapeutics SAS Business Profile
24.2 Kinnov Therapeutics SAS Alcohol Addiction Drug Details
24.3 Drug Snapshot
24.3.1 Originator
24.3.2 Collaborator/Co-Developer
24.3.3 Route of Administration
24.3.4 Orphan Drug/Fast Track/Special Designation
24.3.5 Geography
24.3.6 Type of Molecular Entity
24.3.7 Current Status
24.4 Drug Overview
24.5 Drug Mechanism of Action
24.6 Clinical/Pre-clinical Trial Details
24.7 Latest Drug Developments

25 Kyorin Pharmaceutical Co Ltd Alcohol Addiction Pipeline Details
25.1 Kyorin Pharmaceutical Co Ltd Business Profile
25.2 Kyorin Pharmaceutical Co Ltd Alcohol Addiction Drug Details
25.3 Drug Snapshot
25.3.1 Originator
25.3.2 Collaborator/Co-Developer
25.3.3 Route of Administration
25.3.4 Orphan Drug/Fast Track/Special Designation
25.3.5 Geography
25.3.6 Type of Molecular Entity
25.3.7 Current Status
25.4 Drug Overview
25.5 Drug Mechanism of Action
25.6 Clinical/Pre-clinical Trial Details
25.7 Latest Drug Developments

26 Laboratorio Farmaceutico CT Srl Alcohol Addiction Pipeline Details
26.1 Laboratorio Farmaceutico CT Srl Business Profile
26.2 Laboratorio Farmaceutico CT Srl Alcohol Addiction Drug Details
26.3 Drug Snapshot
26.3.1 Originator
26.3.2 Collaborator/Co-Developer
26.3.3 Route of Administration
26.3.4 Orphan Drug/Fast Track/Special Designation
26.3.5 Geography
26.3.6 Type of Molecular Entity
26.3.7 Current Status
26.4 Drug Overview
26.5 Drug Mechanism of Action
26.6 Clinical/Pre-clinical Trial Details
26.7 Latest Drug Developments

27 Lohocla Research Corp Alcohol Addiction Pipeline Details
27.1 Lohocla Research Corp Business Profile
27.2 Lohocla Research Corp Alcohol Addiction Drug Details
27.3 Drug Snapshot
27.3.1 Originator
27.3.2 Collaborator/Co-Developer
27.3.3 Route of Administration
27.3.4 Orphan Drug/Fast Track/Special Designation
27.3.5 Geography
27.3.6 Type of Molecular Entity
27.3.7 Current Status
27.4 Drug Overview
27.5 Drug Mechanism of Action
27.6 Clinical/Pre-clinical Trial Details
27.7 Latest Drug Developments

28 Mapreg SAS Alcohol Addiction Pipeline Details
28.1 Mapreg SAS Business Profile
28.2 Mapreg SAS Alcohol Addiction Drug Details
28.3 Drug Snapshot
28.3.1 Originator
28.3.2 Collaborator/Co-Developer
28.3.3 Route of Administration
28.3.4 Orphan Drug/Fast Track/Special Designation
28.3.5 Geography
28.3.6 Type of Molecular Entity
28.3.7 Current Status
28.4 Drug Overview
28.5 Drug Mechanism of Action
28.6 Clinical/Pre-clinical Trial Details
28.7 Latest Drug Developments

29 Montisera Ltd Alcohol Addiction Pipeline Details
29.1 Montisera Ltd Business Profile
29.2 Montisera Ltd Alcohol Addiction Drug Details
29.3 Drug Snapshot
29.3.1 Originator
29.3.2 Collaborator/Co-Developer
29.3.3 Route of Administration
29.3.4 Orphan Drug/Fast Track/Special Designation
29.3.5 Geography
29.3.6 Type of Molecular Entity
29.3.7 Current Status
29.4 Drug Overview
29.5 Drug Mechanism of Action
29.6 Clinical/Pre-clinical Trial Details
29.7 Latest Drug Developments

30 Omeros Corp Alcohol Addiction Pipeline Details
30.1 Omeros Corp Business Profile
30.2 Omeros Corp Alcohol Addiction Drug Details
30.3 Drug Snapshot
30.3.1 Originator
30.3.2 Collaborator/Co-Developer
30.3.3 Route of Administration
30.3.4 Orphan Drug/Fast Track/Special Designation
30.3.5 Geography
30.3.6 Type of Molecular Entity
30.3.7 Current Status
30.4 Drug Overview
30.5 Drug Mechanism of Action
30.6 Clinical/Pre-clinical Trial Details
30.7 Latest Drug Developments

31 Pop Test Oncology LLC Alcohol Addiction Pipeline Details
31.1 Pop Test Oncology LLC Business Profile
31.2 Pop Test Oncology LLC Alcohol Addiction Drug Details
31.3 Drug Snapshot
31.3.1 Originator
31.3.2 Collaborator/Co-Developer
31.3.3 Route of Administration
31.3.4 Orphan Drug/Fast Track/Special Designation
31.3.5 Geography
31.3.6 Type of Molecular Entity
31.3.7 Current Status
31.4 Drug Overview
31.5 Drug Mechanism of Action
31.6 Clinical/Pre-clinical Trial Details
31.7 Latest Drug Developments

32 Savant HWP Inc Alcohol Addiction Pipeline Details
32.1 Savant HWP Inc Business Profile
32.2 Savant HWP Inc Alcohol Addiction Drug Details
32.3 Drug Snapshot
32.3.1 Originator
32.3.2 Collaborator/Co-Developer
32.3.3 Route of Administration
32.3.4 Orphan Drug/Fast Track/Special Designation
32.3.5 Geography
32.3.6 Type of Molecular Entity
32.3.7 Current Status
32.4 Drug Overview
32.5 Drug Mechanism of Action
32.6 Clinical/Pre-clinical Trial Details
32.7 Latest Drug Developments

33 Silence Therapeutics Plc Alcohol Addiction Pipeline Details
33.1 Silence Therapeutics Plc Business Profile
33.2 Silence Therapeutics Plc Alcohol Addiction Drug Details
33.3 Drug Snapshot
33.3.1 Originator
33.3.2 Collaborator/Co-Developer
33.3.3 Route of Administration
33.3.4 Orphan Drug/Fast Track/Special Designation
33.3.5 Geography
33.3.6 Type of Molecular Entity
33.3.7 Current Status
33.4 Drug Overview
33.5 Drug Mechanism of Action
33.6 Clinical/Pre-clinical Trial Details
33.7 Latest Drug Developments

34 SK Biopharmaceuticals Co Ltd Alcohol Addiction Pipeline Details
34.1 SK Biopharmaceuticals Co Ltd Business Profile
34.2 SK Biopharmaceuticals Co Ltd Alcohol Addiction Drug Details
34.3 Drug Snapshot
34.3.1 Originator
34.3.2 Collaborator/Co-Developer
34.3.3 Route of Administration
34.3.4 Orphan Drug/Fast Track/Special Designation
34.3.5 Geography
34.3.6 Type of Molecular Entity
34.3.7 Current Status
34.4 Drug Overview
34.5 Drug Mechanism of Action
34.6 Clinical/Pre-clinical Trial Details
34.7 Latest Drug Developments

35 Tonix Pharmaceuticals Holding Corp Alcohol Addiction Pipeline Details
35.1 Tonix Pharmaceuticals Holding Corp Business Profile
35.2 Tonix Pharmaceuticals Holding Corp Alcohol Addiction Drug Details
35.3 Drug Snapshot
35.3.1 Originator
35.3.2 Collaborator/Co-Developer
35.3.3 Route of Administration
35.3.4 Orphan Drug/Fast Track/Special Designation
35.3.5 Geography
35.3.6 Type of Molecular Entity
35.3.7 Current Status
35.4 Drug Overview
35.5 Drug Mechanism of Action
35.6 Clinical/Pre-clinical Trial Details
35.7 Latest Drug Developments

36 VM Discovery Inc Alcohol Addiction Pipeline Details
36.1 VM Discovery Inc Business Profile
36.2 VM Discovery Inc Alcohol Addiction Drug Details
36.3 Drug Snapshot
36.3.1 Originator
36.3.2 Collaborator/Co-Developer
36.3.3 Route of Administration
36.3.4 Orphan Drug/Fast Track/Special Designation
36.3.5 Geography
36.3.6 Type of Molecular Entity
36.3.7 Current Status
36.4 Drug Overview
36.5 Drug Mechanism of Action
36.6 Clinical/Pre-clinical Trial Details
36.7 Latest Drug Developments

37 Zynerba Pharmaceuticals Inc Alcohol Addiction Pipeline Details
37.1 Zynerba Pharmaceuticals Inc Business Profile
37.2 Zynerba Pharmaceuticals Inc Alcohol Addiction Drug Details
37.3 Drug Snapshot
37.3.1 Originator
37.3.2 Collaborator/Co-Developer
37.3.3 Route of Administration
37.3.4 Orphan Drug/Fast Track/Special Designation
37.3.5 Geography
37.3.6 Type of Molecular Entity
37.3.7 Current Status
37.4 Drug Overview
37.5 Drug Mechanism of Action
37.6 Clinical/Pre-clinical Trial Details
37.7 Latest Drug Developments

38. Latest Alcohol Addiction Drug Pipeline Developments, 2019

39. Appendix
39.1 About Us
39.2 Sources and Methodology
39.3 Contact Information
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Adial Pharmaceuticals LLC
  • Amygdala Neurosciences Inc
  • Arbor Pharmaceuticals LLC
  • Assuage Pharmaceuticals Inc
  • Astraea Therapeutics LLC
  • AstraZeneca Plc
  • BioCorRx Inc
  • Bionex Pharmaceuticals LLC
  • Bioprojet SCR
  • Chronos Therapeutics Ltd
  • Corcept Therapeutics Inc
  • Curemark LLC
  • EpiVario Inc
  • Ethypharm SA
  • H. Lundbeck AS
  • Heptares Therapeutics Ltd
  • Indivior Plc
  • Johnson & Johnson
  • Kinnov Therapeutics SAS
  • Kyorin Pharmaceutical Co Ltd
  • Laboratorio Farmaceutico CT Srl
  • Lohocla Research Corp
  • Mapreg SAS
  • Montisera Ltd
  • Omeros Corp
  • Pop Test Oncology LLC
  • Savant HWP Inc
  • Silence Therapeutics Plc
  • SK Biopharmaceuticals Co Ltd
  • Tonix Pharmaceuticals Holding Corp
  • VM Discovery Inc
  • Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown
Adroll
adroll